The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS
Open accessAbstract
Neuroinflammation is a prominent pathological feature in the spinal cords of patients with amyotrophic lateral sclerosis (ALS), as well as in transgenic mouse models of inherited ALS, and is characterized by activated microglia. Earlier studies showed that activated microglia play important roles in both motoneuron protection and injury. More recent studies investigating the pathoprogression of disease in ALS mice have demonstrated that the in vivo activation states of microglia, including their anti- versus pro-inflammatory responses, are best characterized as a continuum between two extreme activation states which are represented as a neuro-protective M2 (alternatively-activated) phenotypic state or an injurious/toxic M1 (classically-activated) state; a more complete understanding and determination the temporal transformation of microglia activation states in the ALS disease pathoprogression is therefore warranted. In the current study, we demonstrated a phenotypic and functional transformation of adult ALS mice microglia that overexpress mutant superoxide dismutase (mSOD1). mSOD1 microglia isolated from ALS mice at disease onset expressed higher levels of Ym1, CD163 and BDNF (markers of M2) mRNA and lower levels of Nox2 (a marker of M1) mRNA compared with mSOD1 microglia isolated from ALS mice at end-stage disease. More importantly, when co-cultured with motoneurons, these mSOD1 M2 microglia were neuroprotective and enhanced motoneuron survival than similarly co-cultured mSOD1 M1 microglia; end-stage mSOD1 M1 microglia were toxic to motoneurons. Our study documents that adult microglia isolated from ALS mice at disease onset have an M2 phenotype and protect motoneurons whereas microglia isolated from end-stage disease ALS mice have adopted an M1 phenotype and are neurotoxic supporting the dual pheno-types of microglia and their transformation during disease pathoprogression in these mice. Thus, harnessing the neuroprotective potential of microglia may provide novel avenues for ALS therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alternative activation of macrophages: mechanism and functions
Gordon, S., & Martinez, F. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.007 · Cited by 4,197 · cited 1×
“In contrast, M2 microglia block proinflammatory responses, and produce high levels of anti-inflammatory cytokines and neurotrophic factors (Buechler et al., 2000; Gordon and Martinez, 2010; Tiemessen and Kuhn, 2007).”
BackgroundMicroglial physiology: unique stimuli, specialized responses
Ransohoff, R. M., & Perry, V. H. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132528 · Cited by 1,858
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130 · cited 1×
“Microglia, as a component of the innate immune system, are of hematopoietic origin and colonize the CNS during early development (Beers et al., 2006; McKercher et al., 1996; Ransohoff and Perry, 2009).”
BackgroundWild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice
Clement, A. M., Nguyen, M. D., Roberts, E. A., Garcia, M. L., Boillée, S., Rule, M., McMahon, A. P., Doucette, W., Siwek, D., Ferrante, R. J., et al. (2003) · Science · doi:10.1126/science.1086071 · Cited by 1,100
Beers, D. R., Henkel, J. S., Xiao, Q., Zhao, W., Wang, J., Yen, A. A., Siklos, L., McKercher, S. R., & Appel, S. H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607423103 · Cited by 733
Self-citationBuechler, C., Ritter, M., Orsó, E., Langmann, T., Klucken, J., & Schmitz, G. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.1.97 · Cited by 704
Obstacles and opportunities for understanding macrophage polarization
Murray, P. J., & Wynn, T. A. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0710409 · Cited by 563
Beers, D. R., Henkel, J. S., Zhao, W., Wang, J., & Appel, S. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807419105 · Cited by 466
Self-citationMotor Neurons Are Selectively Vulnerable to AMPA/Kainate Receptor-Mediated InjuryIn Vitro
Carriedo, S. G., Yin, H. Z., & Weiss, J. H. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-13-04069.1996 · Cited by 441
Beers, D. R., Henkel, J. S., Zhao, W., Wang, J., Huang, A., Wen, S., Liao, B., & Appel, S. H. (2011) · Brain · doi:10.1093/brain/awr074 · Cited by 424
Self-citationMicroglia in ALS: The Good, The Bad, and The Resting
Henkel, J. S., Beers, D. R., Zhao, W., & Appel, S. H. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9171-5 · Cited by 353 · cited 6×
“Therefore, a more complete understanding of how these distinct microglial phenotypes temporally influence the ALS disease pathoprogression process is warranted (Appel et al., 2009; Henkel et al., 2009).”
BackgroundMethodSelf-citationExtracellular mutant SOD1 induces microglial‐mediated motoneuron injury
Zhao, W., Beers, D. R., Henkel, J. S., Zhang, W., Urushitani, M., Julien, J., & Appel, S. H. (2010) · Glia · doi:10.1002/glia.20919 · Cited by 288
Self-citationLe, W.-D., Rowe, D., Xie, W., Ortiz, I., He, Y., & Appel, S. H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08447.2001 · Cited by 275
Self-citationAppel, S. H., Beers, D. R., & Henkel, J. S. (2010) · Trends in Immunology · doi:10.1016/j.it.2009.09.003 · Cited by 256 · cited 1×
“Neuroinflammation is a prominent pathological feature in these CNS areas and characterized by the morphological activation of microglia (Appel et al., 2010).”
BackgroundSelf-citationNeuroinflammation modulates distinct regional and temporal clinical responses in ALS mice
Beers, D. R., Zhao, W., Liao, B., Kano, O., Wang, J., Huang, A., Appel, S. H., & Henkel, J. S. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.12.008 · Cited by 198
Self-citationMutant SOD1G93A microglia are more neurotoxic relative to wild‐type microglia
Xiao, Q., Zhao, W., Beers, D. R., Yen, A. A., Xie, W., Henkel, J. S., & Appel, S. H. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04677.x · Cited by 174 · cited 7×
“Our previous reports, and that of others, have established that different microglial responses can mediate motoneuron protection or injury (Beers et al., 2006; Boillée et al., 2006; Xiao et al., 2007).”
BackgroundResultSelf-citationIncreased cytotoxic potential of microglia from ALS‐transgenic mice
Weydt, P., Yuen, E., Ransom, B. R., & Möller, T. (2004) · Glia · doi:10.1002/glia.20062 · Cited by 173
Zhao, W., Xie, W., Xiao, Q., Beers, D. R., & Appel, S. H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04172.x · Cited by 171
Self-citationAloisi, F., Simone, R. D., Cabezas, S. C., Penna, G., & Adorini, L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.1705 · Cited by 167
Innate immunity in amyotrophic lateral sclerosis
Moisse, K., & Strong, M. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.001 · Cited by 157
Gorvel, V. A., Garcès, A., de Bovis, B., Filippi, P., Henderson, C. E., Pettmann, B., & deLapeyrière, O. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990101)55:1<119::aid-jnr13>3.0.co;2-6 · Cited by 154
Carson, M. J., Bilousova, T. V., Puntambekar, S. S., Melchior, B., Doose, J. M., & Ethell, I. M. (2007) · Neurotherapeutics · doi:10.1016/j.nurt.2007.07.002 · Cited by 135
Serpe, C. J., Byram, S. C., Sanders, V. M., & Jones, K. J. (2004) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2004.07.005 · Cited by 47
A Comparative Analysis of Structural Brain MRI in the Diagnosis of Alzheimer’s Disease
Appel, J., Potter, E. L., Shen, Q., Pantol, G., Greig, M. T., Loewenstein, D., & Duara, R. (2009) · Behavioural Neurology · doi:10.1155/2009/103123 · Cited by 39
Cited by
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Kwon, H. S., & Koh, S.-H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00221-2 · Cited by 2,595
Differential Roles of M1 and M2 Microglia in Neurodegenerative Diseases
Tang, Y., & Le, W. (2016) · Molecular Neurobiology · doi:10.1007/s12035-014-9070-5 · Cited by 2,190
M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination
Miron, V. E., Boyd, A., Zhao, J.-W., Yuen, T. J., Ruckh, J. M., Shadrach, J. L., van Wijngaarden, P., Wagers, A. J., Williams, A., Franklin, R. J. M., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3469 · Cited by 1,777
Microglia in neurodegeneration
Hickman, S., Izzy, S., Sen, P., Morsett, L., & El Khoury, J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0242-x · Cited by 1,710
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“356 Reduced mutant levels in microglia did not have much effect on early disease progression, but substantially slowed it later on, 306 emphasizing that microglia in the late stage accelerate disease progression.”
Background
Metadata
- Authors
- Liao, B., Zhao, W., Beers, D. R., Henkel, J. S., & Appel, S. H.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 237
- Issue
- 1
- Pages
- 147-152
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W1987138690
- Cited by
- 438
- References
- 25
- FWCI
- 13.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.